4-Chlorbenzoyl Berbamine, a Novel Derivative of the Natural Product Berbamine, Potently Inhibits the Growth of Human Myeloma Cells by Modulating the NF-κB and JNK Signalling Pathways

References

• Kyle RA, Rajkumar SV. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma 2009;9:278–288.
   PubMedGoogle Scholar
• Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2:927–937.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bergsage lPL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607–618.
   PubMed Web of Science ®Google Scholar
• Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, et al. Arsenic trioxide controls the fate of the PML-RARalphaoncoprotein by directly binding PML. Science 2010;328:240–243.
   PubMed Web of Science ®Google Scholar
• Jin J, Wang JX, Chen FF, Wu DP, Hu J, Zhou JF, et al. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2013;14:599–608.
   PubMed Web of Science ®Google Scholar
• Corson TW, Crews CM. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell 2007;130:769–774.
   PubMed Web of Science ®Google Scholar
• Li SY, Ling LH, Teh BS, Seow WK, Thong YH. Anti-inflammatory and immunosuppressive properties of the bis-benzylisoquinolines: in vitro comparisons of tetrandrine and berbamine. Int J Immunopharmacol 1989;11:395–401.
   PubMed Web of Science ®Google Scholar
• Wong CW, Seow WK, O'Callaghan JW, Thong YH. Comparative effects of tetrandrine and berbamine on subcutaneous air pouch inflammation induced by interleukin-1, tumour necrosis factor and platelet-activating factor. Agents Actions 1992;36:112–118.
   PubMedGoogle Scholar
• Li SY, Jei W, Seow WK, Thong YH. Effect of berbamine on blood and bone marrow stem cells of cyclophosphamide-treated mice. Int J Immunopharmacol 1994;16:245–249.
   PubMed Web of Science ®Google Scholar
• Xu R, Dong Q, Zhao X, Gan X, Wu D, et al. Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. Leuk Res 2006;30:17–23.
   PubMed Web of Science ®Google Scholar
• Wei YL, Liang Y, Xu L, Zhao XY. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway. Anat Rec (Hoboken) 2009;292:945–950.
   PubMedGoogle Scholar
• Ma T, Gu Y, Zhang X, Qiu X et al. Berbamine derivatives: a novel class of compounds for anti-leukemia activity. Eur J Med Chem 2009;44:3293–3298.
   PubMed Web of Science ®Google Scholar
• Liang Y, Zhao XY, Wei YL, Xu RZ. Berbamine induces apoptosis of multiple myeloma RPMI 8226 cells by activating GADD45/JNK pathway. Zhejiang Da Xue Xue Bao Yi Xue Ban 2009;38:439–444.
   PubMedGoogle Scholar
• Liang Y, Zhao XY. Berbamine, a novel nuclear factor kappaB inhibitor, inhibits growth and induces apoptosis in human myeloma cells. Acta Pharmacol Sin 2009;30:1659–1665.
   PubMed Web of Science ®Google Scholar
• Liang Y, Qiu X, Xu RZ, Zhao XY. Berbamine inhibits proliferation and induces apoptosis of KU812 cells by increasing Smad3 activity. J Zhejiang Univ Sci B 2011;12:568–574.
   PubMed Web of Science ®Google Scholar
• Jin X, Wu Y. Berbamine enhances the antineoplastic activity of gemcitabine in pancreatic cancer cells by activating transforming growth factor-beta/Smad signaling. Anat Rec (Hoboken) 2014;297:802–809.
   PubMedGoogle Scholar
• Liu R, Zhang Y, Chen Y, Qi J, Ren S, Xushi MY, et al. A novel calmodulin antagonist O-(4-ethoxyl-butyl)-berbamine overcomes multidrug resistance in drug-resistant MCF-7/ADR breast carcinoma cells. J Pharm Sci 2010;99:3266–3275.
   PubMed Web of Science ®Google Scholar
• Hu ZY, Gong YS, Huang WL. Interaction of berbamine compound E6 and calmodulin-dependent myosin light chain kinase. Biochem Pharmacol 1992;44:1543–1547.
   PubMed Web of Science ®Google Scholar
• Nam S, Xie J, Ma Y, Yang F, Wu J et al. Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells. Mol Oncol 2012;6:484–493.
   PubMed Web of Science ®Google Scholar
• Yang F, Zhao R, Tian Y, Liu L, Horne DA, et al. A novel synthetic derivative of the natural product berbamine inhibits cell viability and induces apoptosis of human osteosarcoma cells, associated with activation of JNK/AP-1 signaling. Cancer Biol Ther 2013;14:1024–1031.
   PubMed Web of Science ®Google Scholar
• Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA,, LaFace DM, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995;182:1545–1556.
   PubMed Web of Science ®Google Scholar
• Grimm S, Bauer MK, Baeuerle PA, Schulze-Osthoff K. Bcl-2 down-regulates the activity of transcription factor NF-kappa B induced upon apoptosis. J Cell Biol 1996;134:13–23.
   PubMed Web of Science ®Google Scholar
• Baldwin Jr. AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649–683.
   PubMed Web of Science ®Google Scholar
• Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be: NF-kappaB is the answer–role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003;22:8961–8982.
   PubMed Web of Science ®Google Scholar
• Ribatti D, Moschetta M, Vacca A. Microenvironment and multiple myeloma spread. Thromb Res 2014;133(Suppl 2):S102–S106.
   Google Scholar
• Matsui W, Wang Q, Barber JP, Brennan S, Smith BD et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008;68:190–197.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J. et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071–3076.
   PubMed Web of Science ®Google Scholar
• Anderson KC, Prince HM. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma. Semin Hematol 2005;42:S1–S2.
   PubMed Web of Science ®Google Scholar
• Joao C, Coelho I, Costa C, Esteves S, Lucio P. Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma–real life experience of a tertiary cancer center. Ann Hematol 2015;94:97–105.
   PubMed Web of Science ®Google Scholar
• Xia Y, Shen S, Verma IM. NF-kappaB, an active player in human cancers. Cancer Immunol Res 2014;2:823–830.
   PubMed Web of Science ®Google Scholar
• Brasier AR. The NF-kappaB regulatory network. Cardiovasc Toxicol 2006;6:111–130.
   PubMed Web of Science ®Google Scholar
• Wang VY, Huang W, Glass C, et al. The transcriptional specificity of NF-kappaB dimers is coded within the kappaB DNA response elements. Cell Rep 2012;2:824–839.
   PubMed Web of Science ®Google Scholar
• Sonoki T, Nakazawa N, Hata H, Taniwaki M, Nagasaki A, Seto M, et al. Amplification and overexpression of the PRAD1/Cyclin D1 gene in a multiple myeloma cell line. Int J Hematol 1998;68:459–461.
   PubMed Web of Science ®Google Scholar
• Lei K, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 2003;100:2432–2437.
   PubMed Web of Science ®Google Scholar
• Zheng X, Zhang Y, Chen YQ, Shi X, Chen F. Inhibition of NF-kappa B stabilizes gadd45alpha mRNA. Biochem Biophys Res Commun 2005;329:95–99.
   PubMed Web of Science ®Google Scholar
• Papa S, Zazzeroni F, Pham CG, Bubici C, Franzoso G. Linking JNK signaling to NF-kappaB: a key to survival. J Cell Sci 2004;117:5197–5208.
   PubMed Web of Science ®Google Scholar
• Zetoune FS, Murthy AR, Shao Z, Hlaing T, Zeidler MG, Li Y, et al. A20 inhibits NF-kappa B activation downstream of multiple Map3 kinases and interacts with the I kappa B signalosome. Cytokine 2001;15:282–298.
   PubMed Web of Science ®Google Scholar
• Chiou VL, Lee JM, Kohn EC. The MAPK pathway across different malignancies: a new perspective. Cancer 2014;120:3446–3456.
   PubMed Web of Science ®Google Scholar
• Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU, Brady JN. Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene 2005;24:6719–6728.
   PubMed Web of Science ®Google Scholar